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CORRECTION Open Access
Correction to: A randomised controlled trial
of a mitochondrial therapeutic target for
bipolar depression: mitochondrial agents,
N-acetylcysteine, and placebo
Michael Berk1,2,3,4*, Alyna Turner1,2,5, Gin S. Malhi6,7,8, Chee H. Ng9, Susan M. Cotton4,10, Seetal Dodd1,2,10,
Yuval Samuni1, Michelle Tanious6, Claire McAulay6, Nathan Dowling9, Jerome Sarris9,11, Lauren Owen12,
Astrid Waterdrinker13, Deidre Smith9 and Olivia M. Dean1,2,3
Correction to: BMC Med
https://doi.org/10.1186/s12916-019-1257-1
The original article [1] contained two minor errors:
1) Author, Chee H. Ng’s middle initial was omitted;
2) The Competing Interests declaration omitted some
information regarding author, Chee H. Ng.
These two errors have since been corrected.
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